J&J's Invokana matches Jardiance's 14% reduction in major CV events—but doubles amputation risk, too

12th June 2017 Uncategorised 0

There’s officially another heart-helping SGLT2 on the block. But this one brings some varied benefits—and amputation risks—along with it.

More: J&J's Invokana matches Jardiance's 14% reduction in major CV events—but doubles amputation risk, too
Source: fierce